KRAS and colorectal carcinoma: In contrast, there was no statistically significant association between KRAS codon 13 gene mutations and OS in studies of CRC patients with anti-EGFR therapy (pooled HR = 1.57, 95% CI: 0.98–2.51, I2 = 61.0%, P = .06) (Fig. 4).